Universität zu Köln

Marnitz, S., Waltar, T., Koehler, C., Mustea, A. and Schoemig-Markiefka, B. (2020). The brave new world of endometrial cancer Future implications for adjuvant treatment decisions. Strahlenther. Onkol., 196 (11). S. 963 - 973. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Full text not available from this repository.

Abstract

Purpose For many decades, endometrial cancer (EC) has been considered as a homogenous tumor entity with good prognosis. The currently valid risk stratification considers clinical and pathological factors. Treatment recommendations differ considerably from country to country. Materials and methods The Cancer Genome Atlas (TCGA) Research Network has shown that ECs should be reclassified into four novel molecular prognostic groups, with the potential of changing adjuvant management of EC patients: ultra-mutated, hyper-mutated, copy-number low, and copy-number high. Clinical examples are shown, and the available literature has been highlighted. The European Society of Gynaecological Oncology (ESGO) guideline for endometrial cancer takes the new classification system into consideration for adjuvant treatment decisions and will be published this year. Results In the near future, we expect new treatment recommendations that may differ considerably from the clinicopathologically driven recommendations on the basis of our deeper insight and better understanding of molecular markers in endometrial cancer. The PORTEC 4a study is the only recruiting study which randomizes patients to adjuvant or no adjuvant treatment on the basis of the aforementioned new classification system. Conclusion The aim of the new classification is a more personalized adjuvant radio(chemo)therapy decision and better oncologic outcomes or avoidance of overtreatment.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Marnitz, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Waltar, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mustea, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schoemig-Markiefka, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-333436
DOI:	10.1007/s00066-020-01632-w
Journal or Publication Title:	Strahlenther. Onkol.
Volume:	196
Number:	11
Page Range:	S. 963 - 973
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1439-099X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RADIOTHERAPY; TRIAL; RADIATION; THERAPY; MARKERS Multiple languages Oncology; Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33343